# Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

Study · id `cardio:ct-nct06750341` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06750341](<https://clinicaltrials.gov/study/NCT06750341>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06750341

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 156 participants.

## Technical summary

Registry record NCT06750341. Randomized; quadruple masking; primary purpose treatment. Start 2025-02 (anticipated); primary completion 2026-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 156 participants (planned count; ClinicalTrials.gov record NCT06750341, source copy `cardio:ctgov-nct06750341-2024-12-27`, retrieved 2026-10-31)
- Planned start: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06750341, source copy `cardio:ctgov-nct06750341-2024-12-27`, retrieved 2026-10-31)
- Primary completion: 2026-06 (anticipated) (ClinicalTrials.gov record NCT06750341, source copy `cardio:ctgov-nct06750341-2024-12-27`, retrieved 2026-10-31)
- Completion: 2026-09 (anticipated) (ClinicalTrials.gov record NCT06750341, source copy `cardio:ctgov-nct06750341-2024-12-27`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06750341-2024-12-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
- Condition: Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Intervention (Drug): QLC7401
- Intervention (Drug): Placebo
- Lead sponsor: Qilu Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Qilu Pharmaceutical Co., Ltd. (`cardio:org-qilu-pharmaceutical-co-ltd`)

## Provenance

Content hash: 36c95ec510bd085cfa8f709e0d4d6324c0edc0d691bdebef980c30ebcde121ad
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
